Process of conversion of continuous (analog) signals, such as the detected MR signal (voltage), into numbers. This is carried out with an analog to digital converter. There are two kinds of discretization involved: the voltage is only measured (sampled) at particular discrete times, and only voltages within a particular range and separated by a particular minimum amount can be distinguished. Voltages beyond this range are said to exceed the dynamic range of the digitizer.

Quick Overview
Please note that there are different common names for this artifact.

Noise introduced into digitized signals by the finite voltage resolution of the digitizer.
You can see the effects of quantization if the noise level is smaller than the digitizer quantum. If the signal dynamic range is too great, the highest intensities from overloading the digitizer may result in the weaker features being lost in the digitization noise.

This can be resolved by using an analog to digital converter with a larger range of sensitivity or by using techniques to reduce the dynamic range, e.g. suppressing the signal from water in order to detect the signal from less abundant compounds.

Interaction between a spin and its neighbors due to their magnetic dipole moments. This is an important mechanism contributing to relaxation rates. In solids and viscous liquids this can result in broadening of the spectral lines.

This sequence type is a TSE counterpart to double echo sequences. To keep the echo train as short as possible, only echoes for PD and T2 weighted images, where the phase encoding gradient has a small amplitude, are measured separately. The echoes that determine resolution are used in both raw data matrices. This reduces the number of echoes required. Also the SAR drops and more slices can be acquired in the same repetition time.

[This entry is marked for removal.]

(July 20, 2009 - EPIX Pharmaceuticals, Inc. announced today that, in light of the company's lack of capital and inability to obtain additional financing or consummate a strategic transaction, it has entered into an Assignment for the Benefit of Creditors, effective immediately, in accordance with Massachusetts law).
EPIX has been a specialty pharmaceutical firm developing targeted contrast agents to improve the capability of MRI as a diagnostic tool for a variety of diseases. Gadofosveset trisodium (formerly MS-325, Vasovist™, now ABLAVARt™), is an injectable intravascular contrast agents designed for multiple vascular imaging applications, including peripheral vascular disease and coronary artery disease. EPIX conducted a pivotal Phase III trial for the detection of peripheral vascular disease, as well as a Phase II feasibility trial for coronary artery disease diagnosis.
To ensure rapid development and adoption of gadofosveset trisodium into clinical practice upon regulatory approval, EPIX pursued an aggressive product development plan and commercialization strategy. The Company established an exclusive, worldwide sales and marketing agreement with Bayer Schering Pharma AG. EPIX also established corporate collaborations with GE Healthcare, Philips Medical Systems and Siemens Medical Systems, the three leading MRI manufacturers, which together account for approximately 80 percent of the MRI machines installed worldwide.
EPIX had other MRI contrast agents under development, most significantly a novel prototype blood clot agent (EP-2104R). Potential clinical applications for this type of agent include detection of deep venous thrombosis, pulmonary embolism and blood clots in the coronary and carotid arteries. Currently, there is no high resolution imaging technique to directly visualize blood clots in patients with suspected cardiovascular disease.